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Abstract
Background: For adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who
had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease
before the ICH, it is unclear whether starting antiplatelet drugs results in an increase in the risk of recurrent ICH or a
beneficial net reduction of all serious vascular events compared to avoiding antiplatelet drugs.
Methods/design: The REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, randomised,
open, assessor-blind, parallel-group, randomised trial comparing starting versus avoiding antiplatelet drugs for adults
surviving antithrombotic-associated ICH at 122 hospital sites in the United Kingdom. RESTART uses a central,
web-based randomisation system using a minimisation algorithm, with 1:1 treatment allocation to which
central research staff are masked. Central follow-up includes annual postal or telephone questionnaires to
participants and their general (family) practitioners, with local provision of information about adverse events
and outcome events. The primary outcome is recurrent symptomatic ICH. The secondary outcomes are:
symptomatic haemorrhagic events; symptomatic vaso-occlusive events; symptomatic stroke of uncertain type;
other fatal events; modified Rankin Scale score; adherence to antiplatelet drug(s). The magnetic resonance
imaging (MRI) sub-study involves the conduct of brain MRI according to a standardised imaging protocol
before randomisation to investigate heterogeneity of treatment effect according to the presence of brain
microbleeds. Recruitment began on 22 May 2013. The target sample size is at least 720 participants in the
main trial (at least 550 in the MRI sub-study).
Discussion: Final results of RESTART will be analysed and disseminated in 2019.
Trial registration: ISRCTN71907627 (www.isrctn.com/ISRCTN71907627). Prospectively registered on 25 April 2013.
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Background
Patients with stroke due to spontaneous intracerebral
haemorrhage (ICH) often have past histories of systemic
arterial hypertension, smoking, and diabetes mellitus.
These risk factors also contribute to the occurrence of
other conditions before ICH, such as ischaemic stroke,
coronary artery disease, and atrial fibrillation. These risk
factors and diseases may also cause vaso-occlusive
events after ICH, which – overall – appear to occur with
a similar frequency to recurrent ICH [1].
Among individuals at high risk because of a prior vaso-
occlusive event, aspirin provides statistically and clinically
significant absolute reductions in all serious vascular
events from 8.2% to 6.7% per year, in all stroke from 2.5%
to 2.1% per year, and in coronary events from 5.3% to
4.3% per year, despite a non-significant increase in the risk
of intracranial haemorrhage [2]. Antiplatelet drugs also
seem to be beneficial for preventing vaso-occlusive events
in patients with atrial fibrillation and no past history of
vaso-occlusive events, without a detectable increase in the
risk of extracranial or intracranial haemorrhage [3]. How-
ever, patients with spontaneous ICH were not included in
the randomised controlled trials (RCTs) contributing to
these analyses [2, 3], but it is likely that the benefits of
secondary prevention with antiplatelet drugs would apply
after ICH (although whether they are outweighed by the
risk of recurrent ICH is unknown).
There are no published RCTs comparing the effects of
starting versus avoiding antiplatelet drugs for the pre-
vention of vaso-occlusive disease in adults after ICH [4].
Four small, non-randomised observational studies have
not identified consistently beneficial or harmful out-
comes associated with starting or avoiding antiplatelet
drugs after ICH [5–8]: one study found that aspirin was
associated with a beneficial reduction in the composite
endpoint of recurrent ICH, ischaemic stroke or acute
coronary syndrome during follow-up in the sub-group of
patients with ICH and indications for aspirin [6], whilst
another study of 104 survivors of lobar ICH found an in-
crease in the subsequent risk of recurrent ICH associ-
ated with aspirin in multivariable analyses [5].
Because the benefits of antiplatelet drugs for the
prevention of vaso-occlusive disease are likely to con-
tinue to apply after ICH and because the effect of
antiplatelet drugs on the risk of recurrent ICH is un-
known, it is reasonable to consider starting antiplatelet
drugs. However, because the published observational
studies have not provided evidence of a substantial in-
crease in the risk of recurrent ICH with antiplatelet
drugs in such patients, a RCT is needed to assess the
balance of benefits and harms. A similarly designed
RCT has proven feasible and acceptable for patients
who had been taking low-dose aspirin before peptic
ulcer bleeding [9].
Therefore, our aim is to conduct a RCT to determine
whether antiplatelet drugs increase the risk of recurrent
symptomatic ICH to an extent that might outweigh any
beneficial reduction in vaso-occlusive disease. The re-
sults of this RCT may indicate whether a subsequent
large-scale RCT is needed to determine whether the
gains from prevention of vaso-occlusive disease with
antiplatelet drugs outweigh the risks of intracranial and
extracranial haemorrhage, and hence whether there is
net benefit for patients after ICH associated with anti-
thrombotic drug use. Here, we report the final version of
the trial protocol, compliant with the SPIRIT reporting
guideline (Additional file 1).
Methods/design
Study setting
At the time of writing, RESTART collaborators are based
at 122 hospital sites in the National Health Service in
the United Kingdom (see the ‘Acknowledgements’ sec-
tion below for a list of these sites and collaborators). In
view of slow recruitment [10], we conducted the Promo-
ting Recruitment using Information Management Effi-
ciently (PRIME) stepped-wedge, cluster randomised study
within a trial (SWAT) at 72 sites to determine whether a
complex intervention could boost recruitment [11, 12].
One hundred and four sites are recruiting participants to
the sub-study, which involves the conduct of brain mag-
netic resonance imaging (MRI) before randomisation ac-
cording to the MRI sequences and parameters specified
by an imaging protocol (www.restarttrial.org/documents/
RESTART_MRI_protocol.pdf).
Eligibility criteria
Inclusion criteria: patient aged 18 years or older; spon-
taneous ICH not attributable to preceding head injury
and either ‘secondary’ to an underlying structural cause
(e.g. aneurysm, tumour, arteriovenous malformation, or
intracranial venous thrombosis), or ‘primary’ (if the in-
vestigator either does not suspect an underlying struc-
tural cause, or it is not detected by further radiographic
investigation); patient had taken an antithrombotic (i.e.
anticoagulant or antiplatelet) drug for the prevention of
vaso-occlusive disease for any length of time before the
onset of the qualifying ICH; patient is at least 24 h after
ICH symptom onset; patient and their physician are
both uncertain about whether to start or avoid antiplate-
let drugs; patient is registered with a general (family)
practitioner (GP); brain imaging study that first diag-
nosed the qualifying ICH is available; consent to ran-
domisation; if eligible for the brain MRI sub-study, the
MRI must be performed after the ICH but before ran-
domisation. Exclusion criteria: ICH due to head injury
or haemorrhagic transformation of an ischaemic stroke,
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in the opinion of the investigator; patient is taking an
anticoagulant drug following ICH; patient is pregnant,
breastfeeding, or of childbearing age and not taking
contraception; patient and carer unable to understand
spoken or written English (local translator is not avail-
able); patients are ineligible for the brain MRI sub-study
if they are claustrophobic or they have a contraindica-
tion to MRI.
Interventions
RESTART randomises participants to policies of starting
or avoiding antiplatelet drugs. The intervention is re-
stricted to the use of one or more of aspirin, dipyrid-
amole (to which prior ICH is not a contraindication in
the Summary of Product Characteristics (SPC)) or clopi-
dogrel (to which only ‘active pathological bleeding’
(judged to occur within the first 24 h of ICH symptom
onset) is a contraindication). The specific antiplatelet
drug(s) and their doses are determined at the discretion
of the consultant responsible for the participant and
should be prescribed to start within 24 h of randomisa-
tion. The comparator is a policy of avoiding antiplatelet
drugs; there is no placebo. Participants may discontinue
antiplatelet drugs (e.g. if a bleeding outcome event
occurs) or if the prescription of a contraindicated medi-
cation is required in a participant taking antiplatelet
drugs (e.g. if a vaso-occlusive outcome event occurs
which requires treatment with an anticoagulant). To in-
crease the likelihood that participants will receive anti-
platelet drugs if allocated to a policy of starting them,
RESTART: encourages the randomising clinician to em-
phasise the importance of adhering to the allocated
treatment policy; writes to the GP shortly after enrol-
ment to alert them to the participant’s inclusion and
treatment allocation in the trial; writes to the participant
at home (when the hospital/clinic discharge form is
received) reminding them of the purpose of RESTART
and the importance of adhering to their treatment
allocation. RESTART monitors adherence in all partici-
pants regardless of treatment allocation by recording
antiplatelet and anticoagulant use: after randomisation
on the discharge form; on annual participant question-
naires; on annual GP questionnaires; and from ad hoc
reports by participants or their carers to the trial coor-
dinating centre.
Outcomes
RESTART uses multiple sources of ascertainment to
detect outcome events, including: the hospital/clinic
discharge form after randomisation; annual participant
questionnaires; annual GP questionnaires; ad hoc re-
ports from participants, carers, and GPs.
Primary outcome:
 Fatal or non-fatal radiographically or pathologically
proven, recurrent, symptomatic ICH (defined
as the abrupt onset of headache, altered level
of consciousness, or focal neurological deficit,
anatomically referable to a focal collection of
blood predominantly located within the brain
parenchyma (diagnosed on brain imaging or at
autopsy), which was not attributable to prior
trauma or haemorrhagic transformation of an
ischaemic stroke)
Secondary outcomes:
 Fatal (i.e. followed by death within 30 days) or
non-fatal (i.e. not followed by death within 30 days)
serious vascular events:
○ Symptomatic haemorrhagic events
Symptomatic spontaneous or traumatic
extradural haemorrhage, subdural haemorrhage,
subarachnoid haemorrhage, or intraventricular
haemorrhage (not accompanying spontaneous
ICH)
Symptomatic major extracranial
haemorrhage, sub-divided by site (requiring
transfusion or endoscopic treatment or surgery,
or resulting in death within 30 days)
○ Symptomatic vaso-occlusive events
transient ischaemic attack
ischaemic stroke
acute coronary syndrome
peripheral arterial occlusion
mesenteric ischaemia
retinal arterial occlusion
deep vein thrombosis
pulmonary embolism
revascularisation procedures (carotid,
coronary, or peripheral arterial)
cardiac death with symptoms suggestive of
myocardial ischaemia (type 3), or evidence of
arrhythmia
○ Symptomatic stroke of uncertain sub-type
Non-fatal stroke, with brain imaging
performed too late to distinguish ICH from
cerebral infarction
Rapidly fatal stroke, but without radiographic
or pathological confirmation
 Other fatal events
 Annual ratings of participant function completed by
participant or their carer:
○ Simplified modified Rankin Scale postal
questionnaire [13, 14]
○ Structured telephone interview with non-
responders to the postal questionnaire [15]
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Participant timeline
Figures 1 and 2 illustrate the schedule of enrolment,
randomisation, treatment allocation, and assessments
for participants.
Co-enrolment
Inclusion in another research study, including another
RCT but not including a phase I or first-time-into-human
study, does not preclude participation in RESTART as
long as: participants are not overburdened; their inclusion
would not confound RESTART’s results or complicate
attribution of serious adverse events and outcomes; and
co-enrolment has been agreed with the chief investigators
of all studies involved in co-enrolment. Participants in
TICH2 (www.tich-2.org, ISRCTN93732214) may be
co-enrolled in RESTART if at least 21 days have elapsed
after enrolment in TICH2 and the terms of the co-enrol-
ment agreement are upheld [16].
Sample size
There is considerable uncertainty about the absolute
risks of recurrent symptomatic ICH among survivors
who were taking antiplatelet drugs at the time their
index event, but a review of the academic literature sug-
gests that the event rate lies in the range of about 1.8 to
7.4% per year [1]. Similarly, information about the rela-
tive increase in the risk of recurrent ICH on antiplatelet
drugs is scarce, but estimated relative risks from non-
randomised studies have ranged from no excess (relative
risk (RR) = 1) to a four-fold excess (RR = 4) [5–7]. This
study of 720 patients will have excellent power (after all
participants have been followed for at least 2 years) to
detect a doubling of the rate of ICH if the true rate is
4.5% per annum [2, 5, 7, 17], but there would be 93%
power at the 5% significance level to detect a four-fold
increase in risk of recurrent ICH if the annual risk is
only 1%. In both these scenarios the absolute excess risk
of recurrent ICH may be higher than any plausible bene-
fit of treatment, in which case it may be inappropriate to
consider a larger trial designed to demonstrate net bene-
fit. The Trial Steering Committee will review the target
sample size and adjust this based on accruing data on:
the number of primary outcome events, completeness of
follow-up, and the enrolment into specific pre-specified
sub-groups (e.g. lobar ICH location). Contraindications
to MRI, claustrophobia, non-attendances, and schedul-
ing constraints preclude MRI in approximately 25% of
patients, so we hope to obtain brain MRI on approxi-
mately 550 patients before randomisation.
Recruitment and retention
Potentially eligible patients are identified in the everyday
clinical practice of research staff, or referred to them for
assessment of eligibility having been identified elsewhere
(e.g. by clinical staff who are not research staff in secondary
or primary care). Collaborators screen new admissions to
stroke services and may identify patients looked after by
their stroke service for ICH in the past using data extracts
from stroke audits that were developed for the PRIME
SWAT (e.g. https://www.strokeaudit.org/Research/Data-
requests/Accepted-aggregate-data-requests.aspx) [11], or
their stroke service’s database. Collaborators identify pa-
tients at least 24 h after ICH symptom onset and at a time
when uncertainty arises about whether to avoid or start an-
tiplatelet drugs. There is no specific time window for iden-
tifying participants, so they may be recruited during their
hospital admission for the qualifying ICH or at a later stage
in an outpatient clinic. The principal investigator or
physician with delegated responsibility is responsible for
confirming eligibility, ensuring informed consent is ob-
tained and that the informed consent form is completed,
signed and dated by all parties and faxed to the RESTART
trial office before randomisation. Local research staff follow
the laws that govern consent procedures in their jurisdic-
tion, in particular those governing incapacitated adults: if a
patient lacks capacity to consent for themselves then a per-
sonal/legal/professional representative may provide con-
sent on the patient’s behalf. Consent must also be
provided explicitly if the participant is to undergo
Fig. 1 A flowchart describing the REstart or STop Antithrombotics
Randomised Trial (RESTART) trial design
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brain MRI specifically for RESTART. Annual follow-
up is coordinated by the trial coordinating centre,
and begins with a postal questionnaire to each partic-
ipant’s GP (followed by a telephone reminder if
required) to establish each participant’s vital status,
the occurrence of primary and secondary outcome
events, hospital admissions, a recent blood pressure
(BP) measurement, a list of current medications (spe-
cifically enquiring about antithrombotic and antihy-
pertensive drugs), and up-to-date contact details for
the participant. If the participant is still alive and ap-
propriate for questionnaire follow-up, the participant
will be sent a postal questionnaire (followed by a tele-
phone reminder if required) to establish the occur-
rence of primary and secondary outcome events,
hospital admissions, antiplatelet drug use, and their
current modified Rankin Scale score [13–15]. If the
participant does not have capacity or cannot speak
English, their carer will be asked to complete and re-
turn the forms. If the follow-up information cannot
be obtained by either postal or telephone question-
naire the local research team is asked to assist. The
chief investigator (RA-SS) makes the final attempt to
obtain missing GP/participant follow-up. A telephone
helpline is available for participants, carers or GPs to re-
port or discuss outcome events. These methods have been
reviewed and approved by the patient reference group for
the Research to Understand Stroke due to Haemorrhage
(RUSH) programme (www.RUSH.ed.ac.uk).
Allocation
Having obtained consent, the researcher collects the base-
line data necessary to complete a randomisation form, en-
ters the participant’s baseline data into a computerised
central randomisation service by means of a secure
round-the-clock web interface or a telephone call to the
trial office during office hours (if the web interface is not
operational). The web interface checks these baseline data
for completeness and consistency. To avoid predictable
alternation of treatment allocation (and potential
Fig. 2 Schedule of enrolment, interventions, and assessments
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consequent loss of allocation concealment) a minimisation
algorithm randomly allocated the first participant with a
probability of 0.5 to one arm of the trial, but the random-
isation algorithm for each subsequent participant involves
adaptive stratification (i.e. minimisation) and allocates
them with a probability of 0.8 to the group which mini-
mises differences between the two arms of the trial with
respect to five variables collected by research staff at base-
line. The participant is then allocated a unique study iden-
tification number and their allocation to starting or
avoiding antiplatelet drugs is displayed on the web inter-
face and in an email to all local research staff at the
hospital site, having been concealed until that point. If the
participant is allocated to starting antiplatelet drugs, they
are reminded about the antiplatelet drug that would be
prescribed as stated on the randomisation form.
Masking (blinding)
Treatment allocation in RESTART is not masked, and
therefore it is open to participants, the clinicians caring
for them in secondary and primary care, and local re-
search staff. Central research staff carrying out follow-up
are masked to participants’ treatment allocation when
obtaining information (questionnaires and the trial data-
base do not reveal treatment allocation to them), as are
outcome event adjudicators (they review source docu-
mentation of events that might be outcomes with identi-
fiable and treatment information redacted).
Data collection methods
Research staff at collaborating hospital sites collect all
baseline data on demographics, co-morbidities, the quali-
fying ICH, and treatments from participants or their med-
ical records. The patient’s hospital consultant indicates the
intended antiplatelet therapy if randomised to starting an-
tiplatelet drugs, which is collected before randomisation.
Validation rules embedded within the web interface en-
sure 100% completeness of baseline data. Images that di-
agnosed the qualifying ICH and any brain MRI sub-study
images that were obtained before randomisation are cop-
ied in Digital Imaging and Communications in Medicine
(DICOM) format, pseudonymised with the participant ID,
and sent to the trial coordinating centre after randomisa-
tion. Following receipt, the RESTART imaging manager
checks each imaging study to ensure that it relates to the
appropriate participant at the appropriate time, that it is
the appropriate modality, and that all the required images
and sequences have been sent; after quality assurance
these images are uploaded to an electronic archive and al-
located to one of a panel of consultant neuroradiologists
via the in-house, web-based, systematic image review
system (https://www.ed.ac.uk/clinical-sciences/edinburgh-
imaging/research/imaging-services-for-research/trial-im-
ages-service-smartis) for confirmation of ICH diagnosis,
ICH location, and other radiographic evidence of small-
vessel disease [18–20]. Outcome data are collected using
structured postal/telephone questionnaires (available from
the corresponding author upon reasonable request). Com-
pleteness of follow-up information is maximised by pre-
venting the inclusion of participants who do not have a
GP, monitoring completeness of follow-up at fortnightly
team meetings, limiting the collection of unnecessary data
from investigators and participants, emphasising retention
of participants until the end of the trial, and ensuring that
participants’ contact details are kept up to date. There are
no provisions for ancillary and post-trial care given that
the intervention being tested is available in standard clin-
ical practice.
Data management
All records are kept in a secure storage area with limited
access, clinical information will not be released without
the written permission of the participant, and research
staff may not disclose or use for any purpose other than
performance of the study, any data, record, or other un-
published, confidential information disclosed to them for
the purpose of the study. All research staff must comply
with the requirements of the Data Protection Act 1998
with regard to the collection, storage, processing and dis-
closure of personal information and uphold the Act’s core
principles. Data completeness, range, and consistency
checks are performed at randomisation and hospital/clinic
discharge, as well as on imaging data collection forms. In-
complete data on follow-up forms are chased by the chief
investigator. Documentation about RESTART’s data man-
agement procedures can be obtained from the corre-
sponding author upon reasonable request.
Statistical methods
We intend to publish a final Statistical Analysis Plan as
an update to this protocol before the database is locked
for analysis and the results are known. In order to pre-
serve fully the huge benefit of randomisation, we will in-
clude all randomised participants in the analysis
(irrespective of whether they adhere to the allocated
treatment), all retained in the group to which they were
allocated (i.e. ‘as-randomised’). This will comprise a
Kaplan-Meier survival analysis of time to first outcome
event after randomisation. Follow-up will be censored at
death (unrelated to an outcome event), last available
follow-up, or voluntary withdrawal from the trial. We
will compare the survival function in the two trial arms
using a Cox proportional hazards regression model,
adjusting for all the covariates included in the minimisa-
tion algorithm, and presenting the result as an estimated
adjusted hazard ratio with its corresponding 95% CI. We
will also report the unadjusted estimate of the hazard
ratio and its corresponding 95% CI, together with the
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result of the log-rank test. We will use available data and
not impute missing data. We will analyse heterogeneity
of treatment effect using statistical tests of interaction.
Data monitoring
A Data Monitoring Committee (DMC), which is inde-
pendent of the sponsor, oversees the safety of participants
in the trial, according to the terms of reference in the
DMC charter, which is available from the corresponding
author on reasonable request. During the period of re-
cruitment into the study, interim analyses of the baseline
and follow-up data are supplied, in strict confidence, to
the chairman of the DMC, along with any other analyses
that the committee may request. In the light of these ana-
lyses, the DMC will advise the independent chair of the
Trial Steering Committee if, in their view, the randomised
comparisons have provided both (1) ‘proof beyond reason-
able doubt’ that for all, or some, the treatment is clearly
indicated or clearly contra-indicated and (2) evidence that
might reasonably be expected to materially influence fu-
ture patient management. Appropriate criteria of proof
beyond reasonable doubt cannot be specified precisely,
but the DMC will work on the principle that a difference
of at least three standard errors in an interim analysis of a
major outcome event (e.g. the primary outcome) may be
needed to justify halting, or modifying, a trial before the
planned completed recruitment. This criterion has the
practical advantage that the exact number of interim ana-
lyses would be of little importance, and so no fixed sched-
ule is proposed. Unless this happens, however, the Trial
Steering Committee, the collaborators and central admin-
istrative staff will remain ignorant of the interim results.
Harms
RESTART is a pragmatic RCT involving antiplatelet
drugs which have well-established safety profiles. The
trial will routinely collect data on outcomes, serious
adverse events (SAEs), and serious unexpected adverse
reactions (SUSARs), and these will be reviewed by the
independent DMC. The trial procedures are based on
routine clinical procedures and include (1) prescription
of antiplatelet drugs in routine clinical practice for
standard indications, (2) collecting routine clinical in-
formation from the medical records, and (3) informed
consent. There are no complex procedures or interven-
tions for the participants or research staff in this trial.
Clinical management for underlying conditions will re-
main as per each hospital’s standard protocol. Based on
these factors, the probability of harm or injury
(physical, psychological, social or economic) occurring
as a result of participation in this research study is con-
sidered to be low in each of these categories. The
university has insurance in place (which includes no-
fault compensation) for negligent harm caused by poor
protocol design by employees of Edinburgh University.
Sites participating in the study will be liable for clinical
negligence and other negligent harm to individuals tak-
ing part in the study and covered by the duty of care
owed to them by the sites concerned. Sites which are
part of the United Kingdom’s Nation Health Service
will have the benefit of NHS Indemnity.
Auditing
The RESTART internal monitoring procedure to assure
appropriate conduct of the trial uses a combination of
central data monitoring and remote self-monitoring un-
less issues are identified that can only be addressed by
site monitoring in accordance with the Monitoring Plan
agreed by the sponsor. This is regularly reviewed during
the course of the trial.
Dissemination policy
This report of the protocol complies with the Standard
Protocol Items: Recommendations for |Interventional
Trials (SPIRIT) 2013 reporting guideline [21, 22]. On
completion of the trial, the data will be analysed and
tabulated, a clinical study report will be prepared in ac-
cordance with Good Clinical Practice (GCP) guidelines,
and a manuscript for publication will be prepared in
accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines. Active collaborators in-
cluded in the delegation logs at sites that have recruited
participants will be included in any listing of collabora-
tors. The primary trial publication will be drafted by a
writing committee whose membership has been
approved by the Trial Steering Committee, who will ap-
prove the manuscript before submission for publication.
Results will be disseminated to participants who have
opted in to receive them at the time of providing in-
formed consent, and via social media channels (https://
twitter.com/BleedingStroke and https://www.facebook.-
com/bleedingstroke).
Data sharing
Ownership of the data arising from this study resides
with the Trial Steering Committee. Consistent with re-
cent guidance [23], access to the datasets generated and/
or analysed during RESTART will be available on rea-
sonable request after the publication of the main results.
Access will be controlled by the chief investigator, with
the approval of the Trial Steering Committee. Trial par-
ticipants or their proxies are provided with assurances
about the maintenance of privacy and confidentiality in
the information leaflet and they are asked to consent to
the statement, ‘I agree that information about me and
my brain scans may be used in other ethically approved
research studies in the future as long as all the informa-
tion (including the images) is anonymised’.
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Discussion
Since RESTART began in 2013, recruitment has been
challenging. We have learned that one in 12 eligible
patients is actually randomised, mostly because morbid-
ity and mortality after ICH and physician certainty are
impediments to recruitment [10]. We have tried to boost
recruitment with a variety of promotional activities, in-
cluding: patient-orientated information on our website
(http://www.restarttrial.org/patient.html), monthly collab-
orator newsletters, annual collaborator meetings, a com-
plex recruitment intervention which has been rolled out
to all sites after the PRIME SWAT was completed [11],
and one-to-one engagement with site investigators by the
chief investigator by telephone and in person.
Other similar RCTs are underway in France (https://
clinicaltrials.gov/ct2/show/NCT02966119) and Scandi-
navia (https://www.clinicaltrialsregister.eu/ctr-search/trial/
2014-002636-13/SE) [4]. The chief investigators of these
studies have formed a Collaboration Of Controlled
Randomised trials of Oral Antithrombotic drugs after
intraCranial Haemorrhage (COCROACH), with the intent
of performing a prospectively planned, individual-patient,
data meta-analysis of these RCTs to maximise power to
detect the effects of antithrombotic drugs in these patients
overall, and in sub-groups of interest (www.ed.ac.uk/clin-
ical-brain-sciences/research/so-start/for-collaborators).
Trial status
The first participant was randomised on 22 May 2013.
Recruitment is on-going and will end on 31 May 2018.
The current protocol is version 7.0, created on 23
December 2015 (all protocol updates since version 3.0,
created 1 February 2013, which was implemented before
randomisation began, have been approved by the spon-
sor and Research Ethics Committee and also communi-
cated to investigators and trial registries).
Additional file
Additional file 1: RESTART protocol SPIRIT Checklist. (DOCX 50 kb)
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Aberdeen Royal Infirmary, Aberdeen: Dr. Mary-Joan MacLeod, Mrs. Beverly
Maclennan, Dr. Rebecca Clarke, Mrs. Vicky Taylor, Mrs. Katrina Klaasen, Mrs.
Nichola Crouch, Mrs. Baljit Jagpal, Dr. Jacqueline Furnace, Mrs. Janice Irvine,
Mrs. Heather Gow, Mrs. Anu Joyson, Miss Sandra Nelson, Dr. Sarah Ross;
Arrowe Park Hospital, Wirral: Dr. Ruth Davies, Ms. Deepa Jose, Miss Naomi
Robinson, Ms. Laura Codd, Mrs. Angela Dodd, Ms. Helen Moroney, Mrs.
Pauline Weir, Mrs. Victoria Little, Dr. Valerie Gott, Dr. Graeme Sangster, Ms.
Paula Owings, Ms. Suja Cherian, Ms. Susan Downham;
Barnet Hospital, Barnet: Dr. Daniel Epstein, Dr. Adam Webber, Dr. Sammie Qureshi,
Mr. Paul Nicholas, Mr. Vinodh Krishnamurthy, Ms. Avani Shukla, Mr. Ifan Jones;
Barnsley Hospital NHS Foundation Trust, Barnsley: Dr. Ashraf Ahmed, Mrs.
Mishell Cunningham, Dr. Tajammal Zahoor, Mrs. Sharon Johnson, Mrs. Carol
Denniss, Dr. Mo Albazzaz;
Bradford Royal Infirmary, Bradford: Dr. Hawraman Ramadan, Dr. Stuart Maguire,
Chris, Patterson, Mrs. Ruth Bellfield, Mrs. Brigid Hairsine, Mrs. Outi Quinn, Mrs.
Michaela Hooley; Calderdale Royal Hospital, Halifax: Dr. Anand Nair, Mr.
Mohammad irfan alam, Mrs. Jill Greig, Dr. Pratap Rana, Mr. Matthew Robinson;
Chesterfield Royal Hospital, Chesterfield: Dr. Mahmud Sajid, Mrs. Margaret
Ball, Mrs. Rachel Gascoyne, Dr. George Ghaly;
City Hospital, Nottingham: Dr. Senthil Raghunathan, Mrs. Judith Clarke, Miss
Gwendoline Wilkes, Dr. Zhe Law, Dr. Jason Appleton, Mr. Oliver Matias, Mr.
Benjamin Jackson, Miss Rekha Keshvara, Miss Katherine Whittamore, Miss
Carla Jordan, Ms. Saima Sheikh, Mr. Jack Roffe, Miss Nicola Gilzeane, Dr.
Kailash Krishnan, Miss Amanda Buck, Mrs. Diane Havard, Mrs. Amanda
Hedstrom, Miss Faye Shelton, Dr. Nikola Sprigg, Mrs. Margi Godfrey;
Countess of Chester NHS Foundation Trust, Chester: Dr. Timothy Webster, Dr.
Syed Haider, Mrs. Samantha Seagrave, Ms. Sandra Leason, Dr. Arumugam
Nallasivan, Dr. Kausic Chatterjee, Ms. Charlotte Perkins;
Derriford Hospital, Plymouth: Dr. Azlisham Mohd Nor, Ms. Nicola Persad, Ms.
Charlotte Eglinton, Mrs. Claire Brown, Mrs. Marie Weinling, Dr. Alex Shah, Dr.
John Baker, Mr. Benjamin Hyams;
Doncaster Royal Infirmary, Doncaster: Dr. Manohar Kini, Mrs. Rosanna Fong,
Dr. Dinesh Chadha, Mrs. Deborah Walstow;
Dorset County Hospital NHS Foundation Trust, Dorchester: Dr. Harald
Proeschel, Mr. Simon Sharpe, Mrs. Sarah Horton, Mrs. Stephanie Jones;
Forth Valley Royal Hospital, Larbert: Dr. Anthony Byrne, Mrs. Caroline
McGhee, Ms. Amanda Smart, Dr. Claire Copeland;
Gloucestershire Royal Hospital, Gloucester: Dr. Dipankar Dutta, Mrs. Rehana
Bakawala, Mrs. Susan O’Connell, Miss Chloe Hughes, Ms. Pauline Brown, Dr.
Fiona Davis, Miss Kayleigh Collins, Ms. Deborah Ward, Ms. Jennifer Turfrey;
Guys and St Thomas, London: Professor Tony Rudd, Ms. Katherine Marks,
Miss Sagal Kullane, Dr. Birns Jonathan, Dr. Ajay Bhalla;
Hairmyres Hospital, East Kilbride: Dr. Brigitte Yip, Mrs. Murdina Bell, Dr. Brian
MacInnes, Mrs. Linda Macliver, Mr. Derek Esson;
Heartlands Hospital, Birmingham: Dr. Rajendra Yadava, Mrs. Samantha
Stafford, Mrs. Julie Reddan, Mrs. Mirriam Sangombe, Dr. Khalid Azhar;
Hereford County Hospital, Hereford: Dr. Colin Jenkins, Dr. Fiona Price, Miss
Claire Hughes, Ms. Lily Mercer;
Hillingdon Hospital, Uxbridge: Dr. Evangelos Vasileiadis, Mrs. Cathy Mason, Dr.
Basaam Aweid, Mrs. Melinda Holden, Dr. Anthea Parry, Mrs. Geraldine Landers;
James Cook University Hospital, Middlesbrough: Dr. David Broughton, Mrs.
Kath Chapman, Mr. Andrew Sigsworth, Dr. Dinesh Tryambake, Mr. Andrew
Young, Ms. Lynn Dixon, Dr. Adrian Bergin;
Monklands Hospital, Airdrie: Dr. Mark Barber, Mr. Derek Esson, Dr. Fiona Brodie;
Morriston Hospital, Swansea: Dr. Talat Anjum, Ms. Lynda Connor, Mrs. Susan
Tucker, Ms. Sarah Thomas, Mrs. Caroline Davies, Dr. Peter Slade, Ms. Shelley
Treadwell, Dr. Mushtaq Wani, Ms. Teresa Beaty, Dr. Manju Krishnan, Mrs.
Lynne Dacey, Miss Jayne Spencer, Miss Leanne Quinn, Dr. Srikanth Chenna,
Ms. Sharon Storton, Mr. Terry Jones, Miss Helen Thompson Jones;
Musgrove Park Hospital, Taunton: Dr. Malik Hussain, Mrs. Jane Homan, Miss
Eliza Foster, Miss Lucy Brotherton, Mrs. Helen Durman, Mr. Nicholas Hunt, Mrs.
Jayne Foot, Mrs. Alison Whitcher, Miss Corinne Pawley, Dr. Mohammad Khan,
Dr. Robert Whiting, Dr. Miriam Harvey, Mrs. Sarah Brown, Miss Leanne Foote;
Nevill Hall Hospital, Abergavenny: Dr. Bella Richard, Mrs. Claire Triscott, Ms.
Mandy Edwards, Mrs. Heidi Lawson, Mrs. Rebecca Wallace, Mrs. Claire Nott,
Sally Moseley, Mr. Steve Buckle, Miss Procter Sarah, Miss Jessica Whiteman;
New Cross Hospital, Wolverhampton: Dr. Ken Fotherby, Ms. Donna Butler,
Ms. Angela Willberry, Dr. Nasar Ahmad, Mrs. Karla Jennings-Preece, Dr.
Farrukh Baig, Mrs. Debbie Morgan, Mrs. Angela Stevens;
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Norfolk and Norwich University Hospital, Norwich: Dr. Kneale Metcalf, Mrs.
Susan McDonald, Mr. Garth Ravenhill, Dr. Ajmal Anversha, Dr. Naval Shinh,
Ms. Rebekah Perfitt, Mr. Richard Greenwood, Dr. Janak Saada, Mrs. Kelly
Waterfield, Mr. Patrick Sutton, Ms. Jenny Jagger, Mrs. Alison Wiltshire;
North Middlesex University Hospital, London: Dr. Robert Luder, Mrs. Venetia
Vettimootal Johnson, Miss Hayley Bridger, Dr. Maneesh Bhargava, Ms. Jill
Gallagher, Dr. Tolu Adesina, Miss Chloe van Someren;
Pinderfields Hospital, Wakefield: Dr. Michael Carpenter, Ms. Marion Walker,
Dr. Andrew Stanners, Ms. Julie Ball, Ms. Linda Jackson, Dr. Prabal Datta, Mr.
Gavin Bateman, Dr. Razik Fathima, Dr. Richard Davey, Mrs. Ann Needle;
Queen Alexandra Hospital, Portsmouth: Dr. Prasad Siddegowda, Dr. Suheil
Ponnambath, Mrs. Anne Suttling, Miss Yasmin Harrington-Davies, Miss Rebecca
Butler, Miss Claire James, Miss Stacey Valentine, Mrs. Tracey Dobson, Dr. Peter
Howard, Dr. Jane Tandy, Mrs. Lisa Hyatt, Dr. David Jarrett, Dr. Afaq Saulat;
Queen Elizabeth Hospital, Birmingham: Dr. Don Sims, Dr. Mark Willmot, Mrs.
Carole Green, Mrs. Rachael Jones, Mr. James Cunningham, Mrs. Susan
Maiden, Dr. Claire Sutton, Mrs. Jennifer Hurley, Dr. Edward Littleton;
Queen Elizabeth Hospital, Kings Lynn: Dr. Raj Shekhar, Mrs. Rachel Crown, Dr.
Iman Ahmed, Sister Tracy Fuller, Mrs. Ellie Gilham, Mrs. Kelly Waterfield;
Queens Hospital, Romford: Dr. Sreeman Andole, Dr. Naveen Gadapa, Miss
Karen Dunne, Dr. Magdalini Krommyda, Miss Evelyne Burssens, Mr. Sam King;
Royal Blackburn Hospital, Blackburn: Dr. Neetish Goorah, Mrs. Angela Bell,
Mrs. Farzana Patel, Dr. Benjamin Tomlinson, Mr. Stephen Duberley, Dr. Arun
Singh, Mrs. Christine Kelly, Miss Jamie Walford;
Royal Cornwall Hospital, Truro: Dr. Frances Harrington, Dr. Christine
Schofield, Mrs. Linda Lucas, Ms. Sam Ellis, Mrs. Kirsty Bond, Dr. Abhijit Mate,
Dr. Katja Adie, Mrs. Ali James, Ms. Bev Maund, Mrs. Gillian Courtauld;
Royal Devon and Exeter Hospital, Exeter: Dr. Paul Mudd, Dr. Anthony
Hemsley, Mr. Kevin Thorpe, Ms. Karin Gupwell, Dr. Anita Goff, Dr. Jane Sword,
Ms. Caroline Roughan, Dr. David Strain, Ms. Julie Cageao, Ms. Angela
Bowring, Ms. Samantha Keenan, Dr. Martin James, Ms. Hayley Kingwell, Dr.
Keniesha Miller;
Royal Hallamshire Hospital, Sheffield: Dr. Kirsty Harkness, Ms. Clare Doyle,
Professor Arshad Majis, Mrs. Kathy Stocks, Dr. Ahmad Maatouk, Mr. Luke
Barron, Mrs. Katy Dakin, Dr. Ralf Lindert, Miss Christine Kamara, Mrs. Pauline
Bayliss, Dr. Jessica Redgrave, Mrs. Faith Kibutu, Dr. Catrin Blank, Dr. Ali Ali, Mrs.
Olesia Balitska, Mrs. Kathryn Birchall, Mrs. Emma Richards, Miss Jo Howe;
Royal Hampshire County Hospital, Winchester: Dr. Nigel Smyth, Dr. Elio
Giallombardo, Mrs. Charlotte Eglinton, Dr. Lucy Sykes, Mrs. Jenny Wilson;
Royal Infirmary, Glasgow: Professor Peter Langhorne, Dr. Christine McAlpine,
Mrs. Louise Humphreys, Dr. Mohammad Shahzad Iqbal, Ms. Ruth Graham, Dr.
Gillian Kerr, Dr. Fiona Wright;
Royal Lancaster Infirmary, Lancaster: Dr. Pradeep Kumar, Dr. Philip Thomas,
Mrs. Charlotte Culmsee, Dr. Isabel Huggett, Miss Linda Dunn, Dr. James Barker;
Royal Liverpool and Broadgreen University Hospital, Liverpool: Dr. Aravind
Manoj, Dr. Paul Fitzsimmons, Miss Paula Lopez, Dr. Nikhil Sharma, Mrs.
Penelope Cox, Mr. Glyn Fletcher, Mr. Mark Wilkinson;
Royal Preston Hospital, Preston: Dr. Hedley Emsley, Ms. Sonia Raj, Ms. Donna
Doyle, Ms. Bindu Gregory, Dr. Shuja Punekar, Dr. Sulaiman Sultan, Mrs. Alison
McLoughlin;
Royal Surrey County Hospital, Guildford: Dr. Kath Pasco, Miss Olga Balazikova,
Dr. Ashraf Nasim, Miss Cassilda Peixoto;
Royal Sussex County Hospital, Brighton: Dr. Ingrid Kane, Dr. Alexandra Pitt-
Ford, Dr. Simon Hervey, Dr. Philip Thompson, Miss Laura Latter, Mrs. Emma
Barbon, Mrs. Joanna Breeds, Professor Chakravarthi Rajkumar, Dr. Nicola
Gainsborough, Mrs. Jane Gaylard;
Royal United Hospital, Bath: Dr. James Choulerton, Dr. Louise Shaw, Mrs.
Barbara Madigan, Ms. Deborah Howcroft, Ms. Suzanne Lucas, Dr. Andrew
Stone, Miss Joanne Avis, Dr. Lukuman Gbadamoshi, Mrs. Denise Button, Ms.
McCann Stephanie, Dr. Lindsey Dow;
Royal Victoria Infirmary, Newcastle upon Tyne: Dr. Michelle Davis, Mrs. Teresa
Thompson, Mrs. Valerie Hogg, Mrs. Carole Hays, Mrs. Michelle Fawcett, Ms.
Natalie Atkinson, Mrs. Helen Guy, Mr. Stephen Woodward;
Salford Royal Foundation Trust, Manchester: Dr. Adrian Parry-Jones, Mrs. Sally
Marshall, Mr. Rowilson Jarapa, Ms. Stephanie Lee, Mrs. Louise Harrison, Miss
Mary Johnes, Miss Victoria Oloughlin, Miss Edith Wood, Mrs. Jane Perez, Mrs.
Zin Naing, Mr. Jordi Morell, Ms. Tracy Marsden, Miss Andrea Ingham, Dr. Ilse
Burger, Miss Kelly Marie Shaw, Miss Andrea Hall, Dr. Martin Punter;
Southampton General Hospital, Southampton: Dr. Nic Weir, Dr. Sue Evans,
Miss Ashleigh Walters, Miss Imogen Gartrell, Miss Fiona Smith, Miss Chloe
Cox, Charge Nurse Simon Smith, Miss Shuna Egerton, Miss Robyn Creeden,
Dr. James Richard Marigold, Mr. Alex Blades, Dr. Pam Crawford, Dr. Lucy
Sykes, Dr. Emma Battersby-Wood, Ms. Vanessa Pressly, Mr. Christopher Allen,
Ms. Gabriella Howard;
South Glasgow University Hospital, Glasgow: Professor Keith Muir, Dr.
Dheeraj Kalladka, Mrs. Wilma Smith, Ms. Nicola Day, Dr. Fiona Moreton, Dr.
Bharath Kumar Cheripelli, Dr. Xuya Huang, Mrs. Angela Welch, Dr. Salwa El Tawil,
Dr. Sankaranarayanan Ramachandran, Ms. Caroline Crosbie, Dr. Jennifer Elliot;
St George’s Healthcare NHS Trust, London: Ms. Gillian Cluckie, Dr. Brian
Clarke, Mrs. Nilofer Dayal, Mr. Chukwuka Orefo, Mrs. Temi Adedoyin, Mrs. Rita
Ghatala, Ms. Natasha Clarke, Dr. Val Jones, Dr. Adrian Blight, Dr. Caroline
Lovelock, Mrs. Neha Chopra, Dr. Barry Moynihan, Ms. Kate Kennedy, Ms.
Rebecca Williams, Miss Lourda Kerin, Miss Naomi Jeyaraj, Dr. Lillian Choy, Mr.
Fran Watson, Ms. Sarah Trippier, Ms. Joanna O’Reill;
St Mary’s Hospital, Newport Isle of Wight: Dr. Mohammad Haque, Mr. Stuart
Symonds, Dr. Mehran Maanoosi, Mrs. Jane Herman;
Stepping Hill Hospital, Stockport: Dr. Joseph Vassallo, Dr. Shrivakumar
Krishnamoorthy, Mrs. Helen Cochrane, Mrs. Deborah Walter;
Sunderland Royal Hospital, Sunderland: Dr. Janice O’Connell, Ms. Charlotte
Fox, Dr. Ramesh Krishnamurthy, Ms. Emily Osborne, Mr. Andrew Smith, Ms.
Betty Mokoena, Mrs. Diane Gulliver, Mrs. Helen Brew, Dr. Min Myint, Dr. Nikhil
Majmudar, Dr. George Bunea, Dr. Naweed Sattar;
The Princess Royal Hospital, Telford: Dr. Meena Srinivasan, Dr. Indranil
Mukherjee, Mrs. Nichola Motherwell, Mrs. Denise Donaldson, Dr. Robert
Campbell, Mrs. Frances Hurford;
The Royal Bournemouth Hospital, Bournemouth: Dr. Kamy Thavanesan, Dr.
Owen David, Dr. Divya Tiwari, Mrs. Gail Hann, Mrs. Barbara Longland, Mrs. Jo
Bell, Miss Emily Rogers, Miss Caroline Bagnall, Miss Arshi Iqbal, Mrs. Marketa
Keltos, Dr. Becky Jupp, Mr. Josh Roberts, Mrs. Chantel Cox, Miss Catherine
Ovington;
Torbay District General Hospital, Torquay: Dr. Biju Bhaskaran, Mrs. Joanne
Garfield-Smith, Mrs. Jean Buxton, Mrs. Kathleen Horan, Dr. Afaq Saulat, Mrs.
Georgina Ayres, Mrs. Helen Bearne, Mrs. Dawn Tomlin, Mrs. Susan Szabo, Dr.
Debs Kelly, Dr. Isam Salih, Dr. Harbens Bhakri, Mrs. Pauline Fitzell;
Ulster Hospital, Belfast: Dr. David Wilson, Ms. Belinda Wroath, Dr. Kevin
Dynan, Dr. Michael Power, Ms. Susan Thompson;
Ayr Hospital, Ayr: Dr. Sandip Ghosh, Mrs. Margo Henry, Ms. Danielle Gilmour,
Mrs. Elizabeth Barrie;
University Hospitals Coventry and Warwickshire, Coventry: Dr. Antony
Kenton, Miss Sheila Nyabadza, Miss Irene Martin, Dr. Benjamin Hunt, Hardi
Hassan, Dr. Bander Dallol;
University Hospitals of North Midlands NHS Trust, Stoke-on-Trent: Dr. Girish
Muddegowda, Miss Joanne Hiden, Ms. Holly Maguire, Ms. Jeanette Grocott,
Mrs. Kay Finney, Mr. Adrian Barry, Professor Christine Roffe, Mrs. Sue Lyjko, Dr.
Ranjan Sanyal, Mrs. Alda Remegoso, Dr. Phillip Ferdinand, Mr. Adrian Butler,
Ms. Nenette Abano, Miss Chelsea Causley, Ms. Hayley Denic, Mrs. Racquel
Carpio, Miss Stephanie Stevens, Mr. Andrew Moores, Mrs. Resti Varquez;
University Hospital North Durham, Durham: Dr. Yogish Pai, Dr. David Bruce,
Dr. Sofia Dima, Dr. Vidya Baliga, Dr. Muhammad Naeem, Ms. Gill Rogers, Mrs.
Ellen Brown, Mrs. Rachel Hayman, Dr. Mark Garside, Dr. Mahesh Dhakal, Dr.
Gemma Marie Smith, Mrs. Susan Clayton; West Cumberland Hospital,
Whitehaven: Dr. Enoch Orugun, Mrs. Una Poultney, Ms. Rachel Glover, Ms.
Hannah Crowther, Miss Sarah Thornthwaite;
William Harvey Hospital, Ashford: Dr. Tom Webb, Dr. Eva Beranova, Ms.
Susannah Walker, Mrs. Tracey Cosier, Mrs. Hannah Rudenko, Ms. Linda Cowie,
Ms. Anna Verrion, Miss Audrey Thomson;
Wythenshawe Hospital, Manchester: Dr. Ed Gamble, Bethan Charles, Dr.
Rebecca Grue, Mrs. Sujata Blane, Dr. Adam Hague;
Yeovil District Hospital, Yeovil: Dr. Khalid Rashed, Mrs. Carinna Vickers, Mrs. Diane
Wood, Mrs. Janne Board, Miss Clare Buckley, Mrs. Joanna Allison, Mrs. Sarah Board,
Mrs. Barbara William-Yesson, Mrs. Linda Balian, Mrs. Elizabeth Keeling;
Charing Cross Hospital, London: Dr. Arindam Kar, Dr. Omid Halse, Miss Vinh
Nguyen, Miss Kirsten Harvey, Miss Léjeune Gardener, Miss Sheila Mashate, Ms.
Victoria Tilley, Mr. Peter Wilding, Dr. Olivia Geraghty, Ms. Beth Hazel;
The Royal London Hospital, London: Dr. Thomas Harrison, Ms. Larissa
Cuenoud, Miss Grace Auld, Ms. Esther Erumere, Miss Ozlem Redjep, Miss
Gemma Grimwood, Miss Laura Howaniec, Miss Dionne Hove, Dr. Afraim
Salek-Haddadi, Dr. Kari Saastamoinen, Dr. Lucia Argandona; Royal Victoria
Hospital, Belfast: Dr. Ivan Wiggam, Ms. Aine Wallace, Mrs. Sarah Cuddy, Mrs.
Suzanne Tauro, Mrs. Annemarie Hunter, Dr. Enda Kerr, Dr. Ailsa Fulton;
Epsom General Hospital, Epsom: Dr. Janet Putterill, Dr. Puneet Kakar, Dr.
Ratneshwari Jha, Rachel Gallifent;
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Lister Hospital, Stevenage: Dr. Aparna Pusalkar, Miss Kelly Chan, Dr. Puneet
Dangri, Mrs. Karen Crabtree, Mrs. Hannah Beadle, Mrs. Angela Cook;
Salisbury District Hospital, Salisbury: Dr. Toby Black, Mrs. Julie Cronin, Mrs.
Ruth Fennelly, Mrs. Michele Tribbeck, Mrs. Caroline Clarke, Mrs. Skelton
Miriam, Mrs. Alpha Anthony, Mrs. Denise Mead;
Queen Elizabeth Hospital, Gateshead: Dr. Bernard Esisi, Ms. Maria Bokhari, Dr.
Tim Cassidy, Mrs. Beverley McClelland;
Kings Mill Hospital, Mansfield: Dr. Martin Cooper, Mrs. Inez Wynter, Dr. Anoja
Rajapakse, Dr. Mohammad Nasar;
University Hospital of North Tees, Stockton: Dr. Ijaz Anwar, Ms. Lynn Dixon,
Mrs. Alex Ramshaw, Dr. Arunkumar Annamalai, Mrs. Susan Crawford, Ms. Tarn
Nozedar, Dr. Helen Skinner, Dr. Balakrishna Kumar, Mr. Damian McArdle;
Bristol Royal Infirmary, Bristol: Dr. Clare Holmes, Miss Emily Dodd, Mrs.
Samantha Clarke, Dr. Sarah Caine, Mrs. Pauline Baker, Dr. Peter Murphy, Mrs.
Mairead Osborn, Miss Lucy Belle Guthrie, Mrs. Amy Steele, Dr. Nicola Devitt;
Pilgrim Hospital, Boston: Dr. David Mangion, Mrs. Jo Fletcher, Mrs. Anne
Hardwick, Mrs. Carmen Constantin, Dr. Skarlet Markova, Mrs. Tara Lawrence;
Peterborough City Hospital, Peterborough: Dr. Santhosh Subramonian, Miss
Natalie Temple, Dr. Peter Owusu-Agyei, Mrs. Nicola Butterworth-Cowin;
University College London Hospital, London: Professor David Werring, Miss
Caroline Hogan, Mrs. Maria brezitski, Miss Emma Elliott, Mrs. Nina Francia,
Miss Amy Ashton, Dr. Isabel Hostettler, Miss Nnebuife Oji, Miss Azra Banaras,
Miss Krishna Patel, Ms. Luci Crook, Miss Caroline Watchurst, Dr. Duncan
Wilson, Mr. Ifan Jones, Mrs. Renuka Erande;
Luton and Dunstable NHSFT University Hospital, Luton: Dr. Lakshmanan
Sekaran, Dr. Niaz Mohammed, Ms. Meena Chauhan, Dr. Sakthivel
Sethuraman, Mr. Rohan Simon, Mrs. Kiranjit Bharaj, Mrs. Margaret Tate, Mrs.
Frances Justin, Dr. Duke Phiri;
Ystrad Mynach Hospital, Ystrad Mynach, Newport: Dr. Jonathan Hewitt, Mrs.
Claire Nott, Mrs. Jane Gray, Mrs. Rebecca Wallace, Ms. Rina Mardania, Mrs.
Claire Triscott, Miss Sarah Procter, Mr. Steve Buckle, Miss Jessica Whiteman;
Solihull Hospital, Solihull: Dr. Khaled Elfandi, Mrs. Julie Reddan, Dr. Uzma
Khan, Mrs. Samantha Stafford;
Poole Hospital, Poole: Dr. Suzanne Ragab, Mrs. Kerstin Knops, Miss Emma
Jinks, Mrs. Christine Dickson, Mrs. Laura Gleave, Mrs. Jacqui Leggett, Miss
Judith Dube, Dr. Tatiana Garcia;
Victoria Hospital, Blackpool: Dr. James McIlmoyle, Dr. Sajjad Anwar, Dr. Saikat Dhar,
Mrs. Kirsty Jones, Mrs. Carol Jeffs, Mrs. Christina Dickinson, Ms. Joanne Howard;
Derby Royal Hospital, Derby: Dr. Timothy England, Professor Richard
Donnelly, Mrs. Amanda Hedstrom, Dr. Mohana Maddula;
Leeds General Infirmary, Leeds: Dr. Ahamad Hassan, Mrs. Emelda Veraque,
Miss Mary Kambafwile, Mrs. Linetty Makawa, Dr. Marc Randall, Dr. Vasileios
Papavasileiou, Mr. Dean Waugh;
Sandwell General Hospital, Birmingham: Dr. Sissy Ispoglou, Mrs. Anne Hayes,
Dr. Sandeep Ankolekar, Miss Rachel Evans;
Bedford Hospital, Bedford: Dr. Hlaing Ni, Miss Carol Graham, Mrs. Josin Jose,
Mrs. Josette Milligan, Dr. Bithi Rahman;
Raigmore Hospital, Inverness: Dr. Paul Findlay, Dr. Ashish Macaden, Mr. Ian
Shread;
South West Acute Hospital, Enniskillen: Dr. Breffni Keegan, Ms. Caroline Blair,
Dr. Jim Kelly, Ms. Mandy Doherty;
Prince Charles Hospital, Merthyr Tydfil: Dr. Richard Dewar, Dr. James White,
Ms. Kelly Thomas;
Northwick Park Hospital, Harrow: Dr. David Cohen, Mrs. Anette David, Miss
Emmanuelle Owoyele, Dr. Kelechi Njoku, Mr. Philip Poku, Miss Varthi Sukdeo,
Miss Aberami Chandrakumar, Mrs. Angela Chamberlain, Dr. Mudhar Abbdul-
saheb, Ms. Fenglin Guo, Miss Anne Oshodi, Dr. Radim Licenik, Dr. Joseph
Devine, Dr. Silvie Davies, Dr. Nabeela Nisar, Dr. Rangah Niranchanan, Dr. Tat-
jana Roganova, Ms. Mushiya Mpelembue, Miss Laura Burgess, Dr. Rajaram
Bathula, Dr. Mmua Ngwako;
Leicester Royal Infirmary, Leicester: Dr. David Eveson, Dr. Amit Mistri,
Miss Claire Stephens, Dr. Kashif Musarrat, Ms. Man Yee Lam, Mrs. Saira
Sattar, Mrs. Shagufta Khan, Dr. Mohammed Moqsith, Dr. Lisa Manning,
Mrs. Champa Patel;
John Radcliffe Hospital, Oxford: Dr. Ursula Schulz, Dr. James Kennedy,
Professor Gary Ford, Dr. George Harston, Mrs. Rachel Teal, Dr. Philip
Mathieson, Miss Giulia Lenti, Dr. Ian Reckless;
University Hospital Aintree, Liverpool: Dr. Claire Cullen, Mrs. Sarah Stevenson,
Mrs. Melanie Harrison, Mr. Jordan Ewing, Mrs. Daniela Shackcloth, Dr. Ramesh
Durairaj, Ms. Mellor Zoe, Ms. Tanya Ingram, Dr. Hlaing Thant, Ms. Jenny
Peters, Mrs. Victoria Sutton;
St Richard’s Hospital, Chichester: Dr. Simone Ivatts, Ms. Isobel Amey, Mrs. Lisa
Clayton- Evans, Mrs. Yolanda Baird, Mrs. Moore Sally, Miss Sophie Newton;
Southend University Hospital NHS Foundation Trust, Westcliff on Sea: Dr.
Paul Guyler, Dr. Kheng Xiong Ng, Mrs. Rajalakshmi Orath Prabakaran, Dr.
David Ngo, Dr. Sindhu Rashmi, Dr. Lucy Coward, Dr. Nisha Menon, Dr. Shyam
Kelavkar, Mrs. Swapna Kunhunny, Dr. Devesh Sinha, Dr. Anwer Siddiqui, Dr.
Amber Siddiqui, Dr. Thayalini Loganathan, Mrs. Sharon Tysoe, Dr. Sweni Shah;
Leighton Hospital, Crewe: Dr. Latheef Kalathil, Mrs. Nikki Gautam, Mrs. Julie
Meir, Mr. Duncan Bailey, Dr. Maqsud Salehin, Mr. Richard Miller, Miss Amor
Kelly;
Hull Royal Infirmary, Hull: Dr. Rayessa Rayessa, Miss Alicia Rodgers, Mrs. Lisa
Wilson, Miss Charde Naylor, Miss Sarah Wilson, Miss Emma Clarkson;
Altnagelvin Hospital, Derry/Londonderry: Dr. Mark McCarron, Dr. Ferghal
McVerry, Ms. Caroline Blair, Sister Jacqueline McKee, Ms. Mandy Doherty;
Victoria Hospital, Kirkcaldy: Dr. Vera Cvoro, Dr. Khalil Ullah, Dr. Nicola
Chapman, Ms. Mandy Couser, Mrs. Katrina McCormick, Dr. Sean Mcauley, Dr.
Susan Pound;
West Suffolk Hospital, Bury St Edmonds: Dr. Anne Nicolson, Dr. Javed Imam,
Mrs. Julie White, Mrs. Lisa Wood;
Addenbrookes Hospital, Cambridge: Dr. Eoin O‘Brien, Dr. Niamh Hannon, Mrs.
Sarah Finlay, Ms. Helen Hayhoe, Mr. Dominic Handley, Dr. Siobhan Kelly, Mrs.
Joanne Mcgee, Mrs. Jennifer Mitchell, Mrs. Elaine Amis, Ms. Juliana Sesay, Dr.
Sarah Crisp, Mr. Jobbin Francis.
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